ALEXANDRIA, Va., June 19 -- United States Patent no. 12,331,360, issued on June 17, was assigned to Oncgnostics GmbH (Jena, Germany).
"Risk determination for neoplasia and cancer" was invented by Matthias Durst (Jena, Germany), Ingo B. Runnebaum (Jena, Germany), Martina Schmitz (Jena, Germany) and Alfred Hansel (Jena, Germany).
According to the abstract* released by the U.S. Patent & Trademark Office: "Methods for the determination of the risk of developing neoplasia in a tissue, preferably anogenital tissue, showing no histopathological indications of neoplasia are described. The method is based on the determination of the methylation status of genomic DNA sequences associated with the genes ZNF671, ZNF154, ZNF776, ASTN1, BRINP2, DLX1, M...